Gregory L. Verdine

Co-founder, Wave Life Sciences

Appears in 1 story

Last updated May 30, 2026

Stories

Race to build obesity drugs that spare muscle opens new front beyond GLP-1s

New Capabilities

As of May 2026: Harvard chemistry professor and company co-founder

The biggest knock against blockbuster weight-loss drugs like semaglutide is that up to 40% of weight lost is lean tissue (muscle and bone), not fat. New therapies entering trials target genes to spare muscle.

Updated May 30